MAGIC in practice: Experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas

Journal of Surgical Oncology

Volumn 106, Issue 6, 2012, Pages 748-752

  Reece Smith, A M ^a   Saha, S ^a   Cunnell, M L ^b   Hameed, K ^b   Bessell, E M ^a   Duffy, J P ^a   Madhusudan, S ^b   Parsons, S L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ECF; gastro esophageal adenocarcinoma; MAGIC trial; neoadjuvant chemotherapy; survival

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; STOMACH ADENOCARCINOMA; SUDDEN DEATH; SURGICAL MORTALITY; THROMBOEMBOLISM; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84867877992     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23187     Document Type: Article

References (15)

1. Cancer Research UK: Oesophageal cancer outlook and stats. Accessed October 2011 from: http://www.cancerhelp.org.uk/type/oesophageal-cancer/ treatment/statistics-and-outlook-for-oesophageal-cancer
2. Liu W, Zhang X, Sun W,: Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol 2008; 9: 375-387.
3. Cuschieri A, Joypaul V, Fayers P, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347: 995-999.
4. Allum WH, Hallissey MT, Ward LC, et al.: A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: Interim report. Br J Cancer 1989; 60: 739-744.
5. MRC Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
6. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
7. Hyngstrom JR, Posner MC,: Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; 101: 299-304.
8. Allum WH, Stenning SP, Bancewicz J, et al.: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
9. Cunningham D, Starling N, Rao S, et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
10. Fareed KR, Kaye P, Soomro IN, et al.: Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009; 58: 127-143.
11. Fareed KR, Ilyas M, Kaye PV, et al.: Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology 2009; 55: 399-406.
12. Lv J, Cao XF, Zhu B, et al.: Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 2009; 15: 4962-4968.
13. Chua Y, Cunningham D,: The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice. Ann Surg Oncol 2007; 14: 2687-2690.
14. National Oesophago-gastric Cancer Audit 2010: An audit of the care received by patients with Oesophago-gastric cancer in England and Wales. Third annual report. Accessed October 2011 from: http://www.ic.nhs.uk/services/ national-clinical-audit-support-programme-ncasp/audit-reports/ oesophago-gastric-cancer
15. Fareed KR, Al-Attar A, Soomro IN, et al.: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102: 1600-1607.